Validation of the Fatigue Severity Scale in a Swiss Cohort

Valko, Philipp O.; Bassetti, Claudio L.; Bloch, Konrad E.; Held, Ulrike; Baumann, Christian R.

doi:10.1093/sleep/31.11.1601

Cited by 554 publications

(462 citation statements)

References 20 publications

Supporting

Mentioning

418

Contrasting

Unclassified

Order By: Relevance

“…This is sustained by the fact that approximately half of the patients reacted positively to the innovative nutriceutical treatment that increases the activity of PDH, either directly or indirectly via the inhibition of the pyruvate dehydrogenase kinase activity. In the responders the FSS score was reduced to values similar to those reported in healthy subjects [18]. However, as many patients did not experience any beneficial effect.…”

Section: Discussionsupporting

confidence: 58%

“…The results of these questionnaires were calculated as sum of scores given per item divided by the maximum score and expressed (%), and also as average score per 9 items given in the FSS. When applying the latter calculation, the average score of healthy subjects is 3.0 [18].They were given the innovative nutriceutical, and returned after 1 and 3 months to report the effect of treatment and to complete the questionnaire once again.…”

Section: Durationmentioning

confidence: 99%

See 1 more Smart Citation

A Novel Nutriceutical Treatment of Myalgic Encephalitis/Chronic Fatigue Syndrome (ME/CFS): “What it is and what it is not”

Comhaire¹

2017

Intern Med

View full text Add to dashboard Cite

Ten patients suffering from pathology considered to be refractory ME/CFS have been prospectively offered treatment with a novel nutriceutical that increases the activity of pyruvate dehydrogenase and enhances mitochondrial energy production by the aerobic metabolism of the Kreb's cycle. Whereas half of the patients presented highly significant improvement of their health and condition, the other half did not experience any benefit. The latter patients were found to suffer from different pathology that should be classified as "ME/CFS-nondisease".

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Durationmentioning

confidence: 99%

A Novel Nutriceutical Treatment of Myalgic Encephalitis/Chronic Fatigue Syndrome (ME/CFS): “What it is and what it is not”

Comhaire¹

2017

Intern Med

View full text Add to dashboard Cite

show abstract

“…The Fatigue Severity Scale was originally described by Krupp et al [4] and was studied in patients with multiple sclerosis and systemic lupus erythematosus (SLE). The FSS has been further validated [24] and has also been utilized in other diseases such as hepatitis C [25] and Parkinson's disease [26] where fatigue is one of the most commonly reported symptoms. Fatigue is routinely measured in COPD using the St. George's and Chronic Respiratory questionnaires [27], however the FSS scale has not been widely utilized.…”

Section: Discussionmentioning

confidence: 99%

Effects of Pulmonary Rehabilitation on Fatigue Severity Scale In Patients with Lung Disease

Talwar

Sahni

John

et al. 2014

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Introduction: Fatigue is a known symptom of advanced lung disease and impacts quality of life and psychological health. Many of these patients undergo pulmonary rehabilitation as part of their therapy. Understanding the effect of pulmonary rehabilitation on fatigue in these patients is important, as one may be able to design more focused rehabilitation programs. The aim of this study is to evaluate the effect of pulmonary rehabilitation on fatigue as measured by the Fatigue Severity Scale (FSS) in patients with advanced lung disease. Material and Methods: Patients were enrolled in a standardized 6 week pulmonary rehabilitation program. They were asked to complete questionnaires to evaluate their self-reported fatigue (FSS), and depression as measured by Geriatric Depression Scale (GDS). The GDS is a self-reported assessment tool used to identify depression in patients. The FSS is a validated instrument that indicates a perception of fatigue that might require medical intervention. Participants completed questionnaires both at baseline and after completing the standardized pulmonary rehabilitation program. Data was analyzed in Statistical Analysis System (SAS). The change in FSS was evaluated using the Wilcoxon signed-rank test. p-values < 0.05 were considered statistically significant. Results: 21 patients (12 females; 9 males; mean age 64.3 ± 11.2 yrs) were considered for the study. Pre-pulmonary rehabilitation FSS scores ranged from 1.6 to 6.7 (mean score of 4.6 ± 1.7). Post pulmonary rehabilitation FSS scores ranged 1.0 to 6.2 (mean score of 3.9 ± 1.6). The median pre-rehabilitation FSS was 5.3 (inter quartile range; Q1–Q3: 3.0–6.1), and median post rehabilitation FSS was 3.9 (inter quartile range; Q1–Q3: 2.6–5.1). There was a significant decrease in FSS scores after completing pulmonary rehabilitation program (p < 0.0208). There was a decrease in GDS (pre-rehabilitation, mean: 5.5 ± 3.6; post-rehabilitation, mean: 4.2 ± 2.9), but this decrease was not statistically significant. The change in GDS correlated with the change in FSS (Spearman Correlation Coefficient 0.525, p < 0.0146). Conclusions: Patients with advanced lung disease reported a measurable component of fatigue. Participating in pulmonary rehabilitation resulted in significant improvement in patient’s self-reported fatigue severity. Further studies are necessary to evaluate and design interventions to improve fatigue in in the setting of advanced lung disease.

show abstract

“…15 The prevalence of fatigue in our sample was compared with the prevalence of fatigue in the general population (fatigue in 18% and severe fatigue in 4%). 16 Participant sex and age were recorded. We defined persons 50 years or older as an older person and grouped participants into two age groups, o50 years and ⩾ 50 years.…”

Section: Outcome Measuresmentioning

confidence: 99%

Fatigue in persons with subacute spinal cord injury who are dependent on a manual wheelchair

et al. 2015

View full text Add to dashboard Cite

Study design: Cross-sectional. Objectives: To determine the prevalence and severity of fatigue in persons with subacute spinal cord injury (SCI), assess whether demographic and lesion characteristics are related to fatigue and determine the relationship with physical fitness and physical behavior. Setting: Measurements were performed 2 months before discharge from inpatient rehabilitation. Methods: Thirty-six persons with subacute SCI, dependent on a manual wheelchair, mean age 43 ± 15 and 83% men, completed the Fatigue Severity Scale (FSS). FSS scores 44 indicated fatigue. We recorded age and lesion characteristics, measured body mass index, measured peak power output and peak oxygen uptake during a maximal handcycling test and determined physical behavior using an accelerometer-based activity monitor. T-tests were used to test for differences in fatigue between subgroups based on age and lesion characteristics, and regression analyses to assess the relationship with physical fitness and physical behavior. Results: Mean FSS was 3.3 ± 1.3. Fatigue, including severe fatigue, was prevalent in 31% (95% confidence interval: 16-46) of participants compared with 18% in the general population. Furthermore, mean fatigue was significantly higher in persons with incomplete compared with complete lesions (t = 2.22, P = 0.03). Mean scores between other subgroups did not differ significantly. Of the physical fitness and physical behavior measures, only peak oxygen uptake tended to be related to more fatigue (B = − 1.47, P = 0.05). Conclusion: Fatigue was prevalent and is of concern in persons with subacute SCI. Those with incomplete lesions seem to be at higher risk. Because fatigue is known to persist among persons with SCI, interventions to reduce fatigue seem necessary.

show abstract

Validation of the Fatigue Severity Scale in a Swiss Cohort

Abstract: This first validation of a fatigue scale in a large sample size demonstrates that the FSS is a simple and reliable instrument to assess and quantify fatigue for clinical and research purposes.

Cited by 554 publications

References 20 publications

A Novel Nutriceutical Treatment of Myalgic Encephalitis/Chronic Fatigue Syndrome (ME/CFS): “What it is and what it is not”

A Novel Nutriceutical Treatment of Myalgic Encephalitis/Chronic Fatigue Syndrome (ME/CFS): “What it is and what it is not”

Effects of Pulmonary Rehabilitation on Fatigue Severity Scale In Patients with Lung Disease

Fatigue in persons with subacute spinal cord injury who are dependent on a manual wheelchair

Contact Info

Product

Resources

About